Literature DB >> 31871106

The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.

Matthew Schwede1, Levi Waldron2, Samuel C Mok3, Wei Wei4, Azfar Basunia1,5, Melissa A Merritt6, Constantine S Mitsiades7, Giovanni Parmigiani1,5, David P Harrington1,5, John Quackenbush5, Michael J Birrer8, Aedín C Culhane9,5.   

Abstract

BACKGROUND: Recent efforts to improve outcomes for high-grade serous ovarian cancer, a leading cause of cancer death in women, have focused on identifying molecular subtypes and prognostic gene signatures, but existing subtypes have poor cross-study robustness. We tested the contribution of cell admixture in published ovarian cancer molecular subtypes and prognostic gene signatures.
METHODS: Gene signatures of tumor and stroma were developed using paired microdissected tissue from two independent studies. Stromal genes were investigated in two molecular subtype classifications and 61 published gene signatures. Prognostic performance of gene signatures of stromal admixture was evaluated in 2,527 ovarian tumors (16 studies). Computational simulations of increasing stromal cell proportion were performed by mixing gene-expression profiles of paired microdissected ovarian tumor and stroma.
RESULTS: Recently described ovarian cancer molecular subtypes are strongly associated with the cell admixture. Tumors were classified as different molecular subtypes in simulations where the percentage of stromal cells increased. Stromal gene expression in bulk tumors was associated with overall survival (hazard ratio, 1.17; 95% confidence interval, 1.11-1.23), and in one data set, increased stroma was associated with anatomic sampling location. Five published prognostic gene signatures were no longer prognostic in a multivariate model that adjusted for stromal content.
CONCLUSIONS: Cell admixture affects the interpretation and reproduction of ovarian cancer molecular subtypes and gene signatures derived from bulk tissue. Elucidating the role of stroma in the tumor microenvironment and in prognosis is important. IMPACT: Single-cell analyses may be required to refine the molecular subtypes of high-grade serous ovarian cancer. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31871106      PMCID: PMC7448721          DOI: 10.1158/1055-9965.EPI-18-1359

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  47 in total

1.  BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis.

Authors:  Gourish Mondal; Matthew Rowley; Lucia Guidugli; Jianmin Wu; Vernon S Pankratz; Fergus J Couch
Journal:  Dev Cell       Date:  2012-07-05       Impact factor: 12.270

2.  A three-gene model to robustly identify breast cancer molecular subtypes.

Authors:  Benjamin Haibe-Kains; Christine Desmedt; Sherene Loi; Aedin C Culhane; Gianluca Bontempi; John Quackenbush; Christos Sotiriou
Journal:  J Natl Cancer Inst       Date:  2012-01-18       Impact factor: 13.506

3.  A stromal gene signature associated with inflammatory breast cancer.

Authors:  Brenda J Boersma; Mark Reimers; Ming Yi; Joseph A Ludwig; Brian T Luke; Robert M Stephens; Harry G Yfantis; Dong H Lee; John N Weinstein; Stefan Ambs
Journal:  Int J Cancer       Date:  2008-03-15       Impact factor: 7.396

4.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Authors:  Samuel C Mok; Tomas Bonome; Vinod Vathipadiekal; Aaron Bell; Michael E Johnson; Kwong-kwok Wong; Dong-Choon Park; Ke Hao; Daniel K P Yip; Howard Donninger; Laurent Ozbun; Goli Samimi; John Brady; Mike Randonovich; Cindy A Pise-Masison; J Carl Barrett; Wing H Wong; William R Welch; Ross S Berkowitz; Michael J Birrer
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

5.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.

Authors:  Tomas Bonome; Douglas A Levine; Joanna Shih; Mike Randonovich; Cindy A Pise-Masison; Faina Bogomolniy; Laurent Ozbun; John Brady; J Carl Barrett; Jeff Boyd; Michael J Birrer
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

6.  The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.

Authors:  A Huijbers; R A E M Tollenaar; G W v Pelt; E C M Zeestraten; S Dutton; C C McConkey; E Domingo; V T H B M Smit; R Midgley; B F Warren; E C Johnstone; D J Kerr; W E Mesker
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

7.  Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

Authors:  Stefan Bentink; Benjamin Haibe-Kains; Thomas Risch; Jian-Bing Fan; Michelle S Hirsch; Kristina Holton; Renee Rubio; Craig April; Jing Chen; Eliza Wickham-Garcia; Joyce Liu; Aedin Culhane; Ronny Drapkin; John Quackenbush; Ursula A Matulonis
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

8.  The Immune Landscape of Cancer.

Authors:  Vésteinn Thorsson; David L Gibbs; Scott D Brown; Denise Wolf; Dante S Bortone; Tai-Hsien Ou Yang; Eduard Porta-Pardo; Galen F Gao; Christopher L Plaisier; James A Eddy; Elad Ziv; Aedin C Culhane; Evan O Paull; I K Ashok Sivakumar; Andrew J Gentles; Raunaq Malhotra; Farshad Farshidfar; Antonio Colaprico; Joel S Parker; Lisle E Mose; Nam Sy Vo; Jianfang Liu; Yuexin Liu; Janet Rader; Varsha Dhankani; Sheila M Reynolds; Reanne Bowlby; Andrea Califano; Andrew D Cherniack; Dimitris Anastassiou; Davide Bedognetti; Younes Mokrab; Aaron M Newman; Arvind Rao; Ken Chen; Alexander Krasnitz; Hai Hu; Tathiane M Malta; Houtan Noushmehr; Chandra Sekhar Pedamallu; Susan Bullman; Akinyemi I Ojesina; Andrew Lamb; Wanding Zhou; Hui Shen; Toni K Choueiri; John N Weinstein; Justin Guinney; Joel Saltz; Robert A Holt; Charles S Rabkin; Alexander J Lazar; Jonathan S Serody; Elizabeth G Demicco; Mary L Disis; Benjamin G Vincent; Ilya Shmulevich
Journal:  Immunity       Date:  2018-04-05       Impact factor: 43.474

9.  Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.

Authors:  Shengzhe Zhang; Ying Jing; Meiying Zhang; Zhenfeng Zhang; Pengfei Ma; Huixin Peng; Kaixuan Shi; Wei-Qiang Gao; Guanglei Zhuang
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

10.  Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.

Authors:  Tsz-Lun Yeung; Jianting Sheng; Cecilia S Leung; Fuhai Li; Jaeyeon Kim; Samuel Y Ho; Martin M Matzuk; Karen H Lu; Stephen T C Wong; Samuel C Mok
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

View more
  13 in total

1.  Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.

Authors:  Juan Chen; Xiaoyan Shi; Lan Xiao; Zelian Li; Zhimin Li; Lei Sun
Journal:  Cancer Med       Date:  2022-04-17       Impact factor: 4.711

2.  Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.

Authors:  Sotirios Lakis; Vassiliki Kotoula; Georgia-Angeliki Koliou; Ioannis Efstratiou; Sofia Chrisafi; Alexios Papanikolaou; Pantelis Zebekakis; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 3.  Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches.

Authors:  Razia Zakarya; Viive M Howell; Emily K Colvin
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

4.  Long non-coding RNA HAL suppresses the migration and invasion of serous ovarian cancer by inhibiting EMT signaling pathway.

Authors:  Ke Wu; Lei Li; Lin Li; Dong Wang
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840

5.  Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.

Authors:  Yousheng Wei; Tingyu Ou; Yan Lu; Guangteng Wu; Ying Long; Xinbin Pan; Desheng Yao
Journal:  PeerJ       Date:  2020-11-24       Impact factor: 2.984

6.  Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.

Authors:  Ludwig Geistlinger; Sehyun Oh; Marcel Ramos; Lucas Schiffer; Rebecca S LaRue; Christine M Henzler; Sarah A Munro; Claire Daughters; Andrew C Nelson; Boris J Winterhoff; Zenas Chang; Shobhana Talukdar; Mihir Shetty; Sally A Mullany; Martin Morgan; Giovanni Parmigiani; Michael J Birrer; Li-Xuan Qin; Markus Riester; Timothy K Starr; Levi Waldron
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

7.  Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.

Authors:  Allison L Hunt; Nicholas W Bateman; Waleed Barakat; Sasha Makohon-Moore; Brian L Hood; Kelly A Conrads; Ming Zhou; Valerie Calvert; Mariaelena Pierobon; Jeremy Loffredo; Tracy J Litzi; Julie Oliver; Dave Mitchell; Glenn Gist; Christine Rojas; Brian Blanton; Emma L Robinson; Kunle Odunsi; Anil K Sood; Yovanni Casablanca; Kathleen M Darcy; Craig D Shriver; Emanuel F Petricoin; Uma N M Rao; G Larry Maxwell; Thomas P Conrads
Journal:  iScience       Date:  2021-06-21

8.  Gene expression profile association with poor prognosis in epithelial ovarian cancer patients.

Authors:  Douglas V N P Oliveira; Kira P Prahm; Ib J Christensen; Anker Hansen; Claus K Høgdall; Estrid V Høgdall
Journal:  Sci Rep       Date:  2021-03-08       Impact factor: 4.379

9.  Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.

Authors:  Wanja Kassuhn; Oliver Klein; Silvia Darb-Esfahani; Hedwig Lammert; Sylwia Handzik; Eliane T Taube; Wolfgang D Schmitt; Carlotta Keunecke; David Horst; Felix Dreher; Joshy George; David D Bowtell; Oliver Dorigo; Michael Hummel; Jalid Sehouli; Nils Blüthgen; Hagen Kulbe; Elena I Braicu
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

10.  High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.

Authors:  Siel Olbrecht; Pieter Busschaert; Junbin Qian; Adriaan Vanderstichele; Liselore Loverix; Toon Van Gorp; Els Van Nieuwenhuysen; Sileny Han; Annick Van den Broeck; An Coosemans; Anne-Sophie Van Rompuy; Diether Lambrechts; Ignace Vergote
Journal:  Genome Med       Date:  2021-07-09       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.